90 related articles for article (PubMed ID: 12224668)
1. Aggressive lipid-lowering in stable patients with coronary artery disease.
Supanich B
J Fam Pract; 1999 Oct; 48(10):749-50. PubMed ID: 12224668
[No Abstract] [Full Text] [Related]
2. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
Deedwania PC;
Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
[TBL] [Abstract][Full Text] [Related]
3. Reversal of atherosclerosis with aggressive lipid lowering.
Farmer JA
Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
[No Abstract] [Full Text] [Related]
4. DUAAL: atorvastatin provided an unexpectedly potent heart benefit in patients with chronic stable angina.
Cardiovasc J Afr; 2008; 19(3):174. PubMed ID: 18568187
[No Abstract] [Full Text] [Related]
5. Avoid angioplasty by lowering cholesterol?
Health News; 1999 Aug; 5(10):5. PubMed ID: 15352287
[No Abstract] [Full Text] [Related]
6. Benefits of atorvastatin in cholesterol lowering.
Farmer JA
Curr Atheroscler Rep; 2003 Mar; 5(2):94-5. PubMed ID: 12573192
[No Abstract] [Full Text] [Related]
7. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Cohen DJ; Carrozza JP; Baim DS
N Engl J Med; 1999 Dec; 341(24):1853-4; author reply 1854-5. PubMed ID: 10610464
[No Abstract] [Full Text] [Related]
8. Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial.
Koren MJ
Am J Med; 2005 Dec; 118 Suppl 12A():16-21. PubMed ID: 16356803
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin and amlodipine co-treatment in ASCOT--LLA shows benefit.
Cardiovasc J S Afr; 2007; 18(1):43-4. PubMed ID: 17392998
[No Abstract] [Full Text] [Related]
10. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Gresser U; Gathof BS
Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
[TBL] [Abstract][Full Text] [Related]
11. [The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
Griebenow R
Internist (Berl); 2005 Mar; 46(3):350-2. PubMed ID: 15696286
[No Abstract] [Full Text] [Related]
12. Coronary revascularization and aggressive lipid lowering.
Pershad A; Kratzer S; Cooper A
J Invasive Cardiol; 1999 Feb; 11(2):87-9. PubMed ID: 10745488
[No Abstract] [Full Text] [Related]
13. [Coronary disease patient has already LDL of 100 mg/dl. Why lipid lowering is still worthwhile].
MMW Fortschr Med; 2005 Mar; 147(12):4. PubMed ID: 15832778
[No Abstract] [Full Text] [Related]
14. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
[No Abstract] [Full Text] [Related]
15. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
16. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations.
Rihal CS; Raco DL; Gersh BJ; Yusuf S
Circulation; 2003 Nov; 108(20):2439-45. PubMed ID: 14623791
[No Abstract] [Full Text] [Related]
17. The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons.
di Sciascio G
Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():41-3. PubMed ID: 18001321
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
19. Is aggressive lipid-lowering therapy preferable to angioplasty in stable coronary artery disease?
Ellis PM
Med J Aust; 2001 Nov; 175(9):492-3. PubMed ID: 11758081
[No Abstract] [Full Text] [Related]
20. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
Stone PH; Lloyd-Jones DM; Kinlay S; Frei B; Carlson W; Rubenstein J; Andrews TC; Johnstone M; Sopko G; Cole H; Orav J; Selwyn AP; Creager MA;
Circulation; 2005 Apr; 111(14):1747-55. PubMed ID: 15809368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
